Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.

Chantal Mathieu Paresh DandonaMoshe PhillipTal OronMarcus LindLars HansenFredrik ThorénJohn XuAnna Maria Langkildenull null

Published in: Diabetes care (2019)

In patients with type 1 diabetes, treatment with dapagliflozin over 24 weeks improved time in range, mean glucose, and glycemic variability without increasing the time spent in the range indicating hypoglycemia.

Keyphrases

type diabetes
glycemic control
blood glucose
cardiovascular disease
big data
electronic health record
clinical trial
machine learning
blood pressure
metabolic syndrome
replacement therapy
artificial intelligence
weight loss